Ocular Therapeutix (OCUL) Misses Q4 EPS by $1.04, Revenues Miss

March 11, 2021 4:04 PM EST
Get Alerts OCUL Hot Sheet
Price: $15.89 -1.61%

EPS Growth %: -128.3%

Today's EPS Names:
CVU, BK, KSU, More
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($1.21), $1.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $7.35 million versus the consensus estimate of $9.76 million.

“The fourth quarter marked considerable commercial, clinical and regulatory progress for the Company,” said Antony Mattessich, President and Chief Executive Officer. “Physician interest in DEXTENZA® remains high, and despite the challenging backdrop of COVID, adoption by ASCs and HOPDs continues to drive strong growth in reported sales. In the fourth quarter of 2020, in-market purchases were in excess of 14,000 billable units, representing sequential quarterly growth of greater than 40%. Beyond DEXTENZA, we have a unique pipeline of ophthalmology product candidates that each target indications within multi-billion dollar segments of the ophthalmology market. In 2021 we look forward to initiating multiple Phase 2 programs.”

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Earnings, Management Comments

Related Entities